LIXTE BIOTECHNOLOGY HOLDINGS, INC.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
In accordance with Section 13 and 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: March 31, 2026 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. |
|---|---|
| (Registrant) |
| By: | /s/ GEORDAN PURSGLOVE |
| Name: | Geordan Pursglove |
| Title: | President and Chief Executive Officer |
In accordance with the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant in the capacity and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ GEORDAN PURSGLOVE | President and Chief Executive Officer | March 31, 2026 |
| Geordan Pursglove | ||
| /s/ PETER STAZZONE | Vice President and Chief Financial Officer | March 31, 2026 |
| Peter Stazzone | ||
| /s/ JASON D. SAWYER | Director | March 31, 2026 |
| Jason D. Sawyer | ||
| /s/ MICHAEL A. HOLLOWAY | Director | March 31, 2026 |
| Michael A. Holloway | ||
| /s/ GUY W. PRIMUS | Director | March 31, 2026 |
| Guy W. Primus | ||
| /s/ LOURDES FELIX | Director | March 31, 2026 |
| Lourdes Felix | ||
-101-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.